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Abstract 
MicroRNAs are a novel class of gene regulators that function as oncogenes or tumor suppressors. 
In our current study, we investigated the role of miR-15a-3p and miR-16-1-3p in the regulation of 
Twist1 expression and EMT process. Our bioinformatics analysis suggested that on the 3’ UTR of 
Twist1, there are two conserved miRNA recognition sites for miR-15a-3p and miR-16-1-3p 
respectively. Interestingly, overexpression of miR-15a-3p and miR-16-1-3p significantly suppressed 
the activity of luciferase reporter containing Twist1-3’ UTR, reduced mRNA and protein level of 
EMT related genes such as TWIST1, N-cadherin, α-SMA and Fibronectin, and repressed MMP9 
and MMP2 activity, as well as cell migration and invasion. Conversely, inhibition of miR-15a-3p and 
miR-16-1-3p significantly increased TWIST1, N-cadherin, α-SMA and Fibronectin protein 
expression. In addition, Twist1 co-transfection significantly ameliorated the loss of cell migration 
and invasion. Moreover, overexpression of miR-15a-3p and miR-16-1-3p dramatically suppressed 
the ability of BGC823 cells to form colonies in vitro and develop tumors in vivo in nude mice. Finally, 
qPCR and Western blot analysis showed that miR-15a-3p and miR-16-1-3p were significantly 
reduced in clinical gastric cancer tissue, whereas Twist1 mRNA and protein were significantly 
up-regulated, suggesting that this aberrant down-regulation of miR-15a-3p and miR-16-1-3p might 
be associated with the abnormal regulation of Twist1 and the EMT process in gastric cancer 
development. Our results help to elucidate a novel and important mechanism for the regulation of 
Twist1 in the development of cancer. 
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Introduction 
As one of the most common malignant tumors, 
gastric cancer (GC) is the fourth most common cancer 
and the second leading cause of cancer mortality 
worldwide [1-3]. Despite advances in diagnosis and 
treatment, the 5-year survival rate of GC is only 20 
percent [4]. Because of the high mortality of GC, early 
diagnosis and treatment has become an urgent issue. 
Previous studies indicated that the occurrence and 
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development of GC is a complicated process that 
involves a variety of cross-linked factors such as 
environmental infection [5], cell proliferation and cell 
cycle dysfunction [6], angiogenesis [7, 8], cell invasion 
and metastasis[9]. Molecular mechanism studies 
showed that GC involves aberrant expression of 
oncogenes, tumor suppressor genes, apoptosis-related 
genes and metastasis-related genes [4]. Recent studies 
have shown that cancer cell metastasis is the primary 
cause of mortality in human GC patients [10, 11]. 
Invasion and metastasis are exceedingly complex 
processes that enable cancer cells to escape from the 
primary tumor mass and colonize new sites [11].  
Growing evidence demonstrated that the 
epithelial-mesenchymal transition (EMT) represent as 
a developmental process plays important roles in 
invasion and metastasis in GC, colorectal cancer, 
breast cancer and liver cancer [12-14]. During cancer 
progression, tumor cells undergoing an EMT process 
acquire mesenchymal cell characteristics, losing 
epithelial markers and gaining cell motility to 
promote cancer cell migration across the basal 
membrane and invasion of the surrounding 
microenvironment [14]. Moreover, the EMT process 
increases tumor cell resistance to apoptosis and 
chemotherapeutic drugs [15]. The EMT process can be 
regulated by a diverse array of tumor-related genes, 
such as Snail1/2, Slug, Zeb1/2, Twist1 and some 
other transcription factors [16-19]. Studies showed 
that the transcription factor Twist1 is important for 
regulating EMT process, and over-expression of 
Twist1 significantly induced cell morphological 
changes as well as increased cell migration and 
invasion ability by regulating the expression of 
E-cadherin, N-cadherin, c-fos and metalloproteinase-9 
[20, 21]. Therefore, Twist1 was suggested to have 
oncogenic properties. For example, microarray 
analysis showed that Twist1 regulates the expression 
of several EMT-related genes to regulate the 
differentiation, adhesion, and proliferation of GC cells 
[22]. In addition, Twist1 is up-regulated in 
GC-associated fibroblasts and contribute to the 
progression of GC cells and poor patient survival [23]. 
Moreover, Qian et al. found that Twist1 was 
over-expressed in NCI-N87 or AGS GC cells and 
promotes GC cell proliferation through the 
up-regulation of FoxM1 [24]. However, the effect and 
mechanism of Twist1 gene activity on cell invasion 
and metastasis of gastric carcinoma remain enigmatic.  
MicroRNAs (miRNAs) are important regulators 
and function as oncogenes or tumor suppressors by 
targeting the 3’ untranslated region (UTR) of 
messenger RNA (mRNA) to induce mRNA 
degradation and suppression of translation [25, 26]. 
Growing evidence suggests that miRNAs play 
important roles in diverse biological processes and the 
dysfunction of miRNAs is involved in the 
development of many types of cancer, including GC 
[27]. Recent studies showed that a series of miRNAs 
serve as key regulators that affect the invasion and 
metastasis by regulating Twist1 in a variety of tumors 
[28-30]. In this study, we use GC cells and 
investigated the role of miR-15a-3p- and miR-16- 
1-3p-mediated gene silencing on the regulation of 
Twist1 expression. We found that Twist1 is a direct 
target of miR-15a-3p and miR-16-1-3p, and the 
Twist1-EMT pathway was suppressed by miR-15a-3p 
and miR-16-1-3p. Moreover, miR-15a-3p and 
miR-16-1-3p negatively regulate Twist1 through 
interacting with the miRNA recognition elements 
(MREs) on the Twist1-3’ untranslated region (Twist1-3’ 
UTR). Further investigation revealed that by targeting 
Twist1, miR-15a-3p and miR-16-1-3p suppressed the 
ability of cancer cells to form colonies in vitro and to 
develop tumors in vivo. Furthermore, the lower 
expression of miR-15a-3p and miR-16-1-3p is 
correlated with substantial induction of Twist1 
expression in human GC tissues, which might 
contribute significantly to the pathogenesis or 
progression of tumor formation. Taken together, our 
data suggest an important regulatory role of 
miR-15a-3p and miR-16-1-3p in the EMT process in 
tumors. Thus, miR-15a-3p, miR-16-1-3p and Twist1 
might be important diagnostic or therapeutic targets 
for EMT process in cancer and other human diseases. 
Materials and Methods 
Plasmid construction 
HA tagged human Twist1-overexpressing 
plasmid pHA-Twist1 was a generous gift of Prof. 
Jianming Chen from Third Institute of Oceanography, 
State Oceanic Administration. For the construction of 
human Twist1-3’UTR, wildtype Twist1-3’UTR 
miR-15a-3p MRE, mutant Twist1-3’UTR miR-15a-3p 
MRE, wildtype Twist1-3’UTR miR-16-1-3p MRE and 
mutant Twist1-3’UTR miR-16-1-3p MRE luciferase 
reporters, the primer pairs shown in Supplemental 
Table S2 (based on the genomic sequences from the 
miRBase (http://www.mirbase.org, Release 19)) were 
designed to amplify five cDNA fragments for the full 
length of Twist1-3’UTR (585 bp, NM_000474.3), a 
truncated Twist1-3’UTR harboring a DNA fragment 
with the wild-type or mutated miR-15a-3p-MRE on 
Twist1-3’UTR (453 bp) and a truncated Twist1-3’UTR 
harboring a DNA fragment with the wild-type or 
mutated miR-16-1-3p-MRE on Twist1-3’UTR (438 bp), 
respectively. The resultant PCR fragments carrying a 
SacI site and a HindIII site were subcloned into the 
pGL3-control vector (Promega), using the SacI and 
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HindIII sites immediately downstream of the stop 
codon of the luciferase cDNA, generating 
pTwist1-3’UTR-luc, p15a-3p-MRE-WT-luc, p15a-3p- 
MRE-MT-luc, p16-1-3p-MRE-WT-luc and p16-1-3p- 
MRE-MT-luc respectively. The resulting plasmids are 
shown in Figure S4 in the Supplemental information 
section. Other plasmids used in this study, See 
Supplemental Materials and Methods section in 
Supplementary Information. 
Cell culture and transient transfection 
Human BGC823 gastric cancer cells were 
obtained from the ATCC (Manassas, VA, USA), and 
the cells were maintained in DMEM medium 
(Cat#12491-015, Gibco, Grand island, NY, USA) 
supplemented with 10% fetal bovine serum 
(Cat#10099141, Gibco, Grand island, NY, USA) and 
incubated in a humidified incubator at 37 ºC in 5% 
CO2. Plasmid DNA, miRNA mimics and miRNA 
inhibitor (anti-sense oligonucleotides) transfections 
were performed with Lipofectamine 2000 reagent 
(Cat#11668-019, Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer's protocol.  
Real-time quantitative PCR (qPCR) analyses of 
mRNAs and miRNAs 
For qPCR analyses of mRNA, reverse 
transcription was performed with TRIzol 
(Cat#15596-018, Invitrogen, Carlsbad, CA, USA)- 
extracted total RNAs using a ReverTra Ace-α® Kit as 
instructed (Cat#FSQ-101, Toyobo, Tokyo, Japan). 
qPCR was performed using the SYBR Green 
Real-Time PCR Master Mix (Cat#QPK-212, Toyobo) 
and the Step One Plus Real-Time PCR system 
(Applied Biosystems Inc., Foster City, CA, USA) using 
appropriate primer pairs as listed in Table S3, 
according to the manufacturers’ protocols and with 
18S rRNA as a control. 
For miRNAs, qPCR was performed with the 
stem-loop primers as reported previously [31]. U6 
RNA served as an internal control. The 
miRNA-specific stem-loop primers listed in Table S3. 
qPCR was performed with total RNAs, using 
universal primer and miRNA-specific reverse 
LNA-primers as listed in Supplementary Table S3, 
with U6 RNA served as an internal control. 
Western blot analyses 
Cell protein lysates were separated in 12% 
SDS-polyacrylamide gels and electrophoretically 
transferred to nitrocellulose membranes (Amersham). 
The detection was achieved using the Immobilon 
Western Chemiluminescent HRP Substrate Kit 
(Cat#WBKLS0500, Millipore, Darmstadt, Germany). 
The antibodies used were listed on Table S4.  
Luciferase reporter assays 
Luciferase reporter activities were determined 
using a Luciferase Reporter Gene Assay System 
(Cat#E1601, Promega, Madison, WI, USA) as 
instructed. About 1 × 105 BGC823 cells were 
transfected with 10 pm of miR-15a-3p or miR-16-1-3p 
mimics and 0.3 μg of luciferase reporter plasmid 
together with 0.1 μg of pSV40-β-galactosidase (4:3:1) 
as indicated. Cells were harvested for luciferase 
activity assays 24 h after the transfection. The 
calibrated value for a proper control was used to 
normalize all other values to obtain the normalized 
relative luciferase units (RLU) representing the 
activities of the Twist1-3’ UTR.  
Gelatin- and casein-zymography analysis 
About 5×105 BGC823 cells were seeded onto 
6-well plates. After 24 hours, cells were transfected 
with 4 μg of pmiR-15a, pmiR-16-1 or the control 
plasmid. 24 hours after the transfection, the cell 
medium were collected and mixed with non-reducing 
SDS gel sample buffer and applied without boiling to 
a 10% polyacrylamide gel containing 0.1% SDS and 1 
mg/ml gelatin or casein solution. After 
electrophoresis, the gels were washed in 50 mmol/l 
Tris-HCl (pH 7.5) containing 0.15 mol/l NaCl, 5 
mmol/l CaC12, 5 μmol/l ZnCl, 0.02% NaN3, 0.25% 
Triton X-100 (three changes) at room temperature, 
and then incubated in the same buffer without Triton 
X-100 (two changes) at 37°C for 20 h. Proteins were 
stained by Coomassie Brilliant Blue R-250 solution.  
Cell migration, invasion and colony formation 
assays 
For wound-healing assays, about 5×105 BGC823 
cells were seeded onto 6-well plates. After 24 hours, 
cells were transfected with 2 μg of pmiR-15a, 
pmiR-16-1 or the control plasmid in the presence or 
absence of 2 μg of pHA-Twist1. After transfection, a 
wound was incised in the center of the confluent 
culture, followed by careful washing to remove 
detached cells and the addition of fresh medium. 
Phase contrast images of the wounded area were 
recorded using an inverted microscope at indicated 
time points. 
Cell migration was analyzed by Transwell 
(Cat#3422, Corning, NY, USA) assays according to the 
manufacturer's instructions. Matrigel invasion assays 
were performed using Millicell inserts coated with 
matrigel (Cat#354480, BD Biosciences, Sparks, MD, 
USA). BGC823 cells were grown and transfected with 
pmiR-15a or pmiR-16-1 in the presence or absence of 
pHA-Twist1 as described before. 24 hours after the 
transfection, 2.5×104 BGC823 cells were seeded per 
upper chambers in serum-free DMEM whereas the 
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lower chambers were loaded with DMEM containing 
5% FBS. After 48 hours, the non-migrating cells on the 
upper chambers were removed by a cotton swab, and 
cells invaded through the matrigel layer to the 
underside of the membrane were stained with a 0.1% 
crystal violet solution and counted manually in eight 
random microscopic fields. 
For colony formation assays, about 5×105 
BGC823 cells were seeded onto 6-well plates. After 24 
hours, cells were transfected with 4 μg of pmiR-15a, 
pmiR-16-1 or the control plasmid. 24 hours after the 
transfection, 200 of treansfected cells were seeded on 
six-well plates and maintained in DMEM containing 
10% FBS for 2 weeks. Cells were fixed with methanol 
and stained with 0.5% crystal violet in 50% methanol 
for 1 hour and colonies larger than 100 μm in diameter 
were counted. 
For soft agar colony formation assays, about 
5×105 BGC823 cells were seeded onto 6-well plates. 
After 24 hours, cells were transfected with 2 μg of 
pmiR-15a, pmiR-16-1 or the control plasmid in the 
presence or absence of 2 μg of pHA-Twist1. 24 hours 
after the transfection, 5×103 transfected BGC823 cells 
were suspended in 2 ml of DMEM containing 0.3% 
agar and 10% serum and added onto a layer of 
medium containing 0.5% agar and 10% serum in a 
6-well plate. 2 ml of medium containing 10% serum 
was added to the dish every other day. After 14 days, 
the number of colonies was measured. 
Animal experiments 
All experimental procedures involving animals 
were performed in accordance with animal protocols 
approved by the Institutional Animal Use and Care 
Committee of Xiamen University. For xenograft 
tumor growth, BGC823 cells were infected with 
LV-miR-Ctrl, LV-miR-15a and LV-miR-16-1 lentivirus 
in the presence or absence of LV-Twist1. 24 hours 
after the infection, cells were harvested and 
suspended in PBS and then inoculated 
subcutaneously (~1 × 106 cells/100 ml/mouse) into 
the right side of the posterior flank of male BALB/c 
athymic nude mouse at 5 to 6 week. Beginning from 
the 7th day after the injection, the size of the tumor 
was measured every 3 days by a Vernier caliper along 
two perpendicular axes. Tumor volume (V) was 
monitored by measuring the length (L) and width (W) 
and calculated with the formula (L × W2) × 0.52. 
Twenty-five days after the injection, the mice were 
sacrificed and the tumors were dissected for further 
analyses. 
Clinical samples 
All clinical samples were collected with the 
informed consent of the patients and study protocols 
that were in accordance with the ethical guidelines of 
the Declaration of Helsinki (1975) and were approved 
by the Institutional Medical Ethics Committee of 
Xiamen University. GC pathological diagnosis was 
verified by at least two pathologists. Twenty human 
GC specimens and paired adjacent epithelial tissues 
were obtained from the Zhongshan Hospital affiliated 
to Xiamen University from 25 January 2014 to October 
2014. 
Other data acquisition, image processing and 
statistical analyses 
Western blot images were captured by Biosense 
SC8108 Gel Documentation System with GeneScope 
V1.73 software (Shanghai BioTech, Shanghai, China). 
Gel images were imported into Photoshop for 
orientation and cropping. Data are the means ± SEM. 
One-way ANOVA with Bonferonni’s post-test was 
used for multiple comparisons and the Student’s t test 
(two-tailed) for pair-wise comparisons. 
Results 
 Twist1 is a direct target of miR-15a-3p and 
miR-16-1-3p 
To identify the potential miRNAs that might 
target Twist1, we analyzed the 3’ UTR sequence of 
human Twist1 with miRanda (http://www. 
microrna.org) algorithms. Our bioinformatics analysis 
suggested that there are two miRNA MREs on human 
Twist1 3’UTR (one MRE for miR-15a-3p and one MRE 
for miR-16-1-3p, Figure 1A), suggesting that these two 
miRNAs might be important regulators for Twist1.  
To determine whether miR-15a-3p and 
miR-16-1-3p regulate Twist1 expression, we 
performed transient transfection studies in cultured 
BGC823 cells. Our quantitative PCR (qPCR) analyses 
indicated that, compared to the control transfected 
group (pFlag-CMV2-transfected group), transfection 
of BGC823 cells with a plasmid carrying miR-15a or 
miR-16-1 precursor (pmiR-15a or pmiR-16-1, see 
supplemental materials and methods) significantly 
increased miR-15a-3p and miR-16-1-3p expression (p 
< 0.001 and p < 0.01, Figure 1B), and this induction of 
the miRNAs led to a 38% (p < 0.05) and 39% (p < 0.05) 
reduction in Twist1 mRNA expression, respectively 
(Figure 1C).  
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Figure 1. Twist1 is a direct target of miR-15a-3p and miR-16-1-3p. (A) bioinformatic prediction of miR-15a-3p and miR-16-1-3p recognition elements on the human 
Twist1-3’ UTR. Analyses were performed with either the mirRanda algorithms. (B) transfection of pmiR-15a and pmiR-16-1 miRNA overexpression plasmids significantly 
increased miR-15a-3p and miR-16-1-3p expression, respectively. BGC823 cells were transfected with pFlag-CMV2 or pmiR-15a or miR-16-1. 24 hours after the transfection, cells 
were harvested for qPCR analysis using miR-15a-3p and miR-16-1-3p specific primers. n = 3, **, p < 0.01; ***, p < 0.001. (C) overexpression of miR-15a-3p and miR-16-1-3p 
significantly reduced the Twist1 mRNA expression level in BGC823 cells. (D) miR-15a-3p and miR-16-1-3p regulate Twist1 by interacting with the 3’ UTR of Twist1. BGC823 cells 
were transfected with miR-15a-3p or miR-16-1-3p mimics and a luciferase reporter plasmid together with pSV40-β-galactosidase (4:3:1) as indicated. Cells were harvested for 
luciferase activity assays 24 h after the transfection. β-galactosidase activity was determined and used for the calibration of luciferase reporter activity. Data are represented as 
the mean ± SEM (n = 3). NS, not significant; **, p < 0.01; ***, p < 0.001.  
 
To further determine whether miR-15a-3p or 
miR-16-1-3p regulate Twist1 by targeting the Twist1-3’ 
UTR, we performed 3’ UTR luciferase reporter assays. 
Firstly we constructed Twist1-3’ UTR-luciferase 
reporter plasmids (see supplemental materials and 
methods) and used them for BGC823 cell 
transfections. Plasmid pTwist1-3’UTR-luc contained a 
full-length sequence for human Twist1-3’ UTR (Figure 
S4). BGC823 cells were co-transfected with 
miR-15a-3p mimics or with miR-16-1-3p mimics and 
luciferase reporter plasmid pTwist1-3’UTR-luc. 
Consistent with the bioinformatics prediction, 
transfection of miR-15a-3p or miR-16-1-3p mimics 
significantly caused a 15% (p < 0.001) or 32% (p < 
0.001) reduction in luciferase activity in BGC823 cells 
cotransfected with pTwist1-3’UTR-luc, respectively 
(Figure 1D). These results suggest that miR-15a-3p 
and miR-16-1-3p repress Twist1 through interacting 
with the MREs on its 3’UTR. Mutational analyses of 
the miR-15a-3p and miR-16-1-3p MRE on Twist1-3’ 
UTR (wildtype MRE plasmid p15a-3p-MRE-WT-luc 
and p16-1-3p-MRE-WT-luc versus mutated MRE 
plasmid p15a-3p-MRE-MT-luc and p16-1-3p- 
MRE-MT-luc) further confirmed the specific 
interaction between miR-15a-3p and miR-16-1-3p and 
Twist1-3’ UTR (Figure 1D). Together, these data 
suggest that Twist1 mRNA was all under the 
post-transcriptional control of miR-15a-3p and 
miR-16-1-3p by target Twist1-3’ UTR. 
 miR-15a-3p and miR-16-1-3p repress Twist1 
and EMT-related genes 
To further probe the function of miR-15a-3p and 
miR-16-1-3p in the regulation of the EMT pathway, 
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we performed transfections in BGC823 cells. Our 
Western blot analysis showed that overexpression of 
miR-15a-3p and miR-16-1-3p significantly decreased 
TWIST1 protein level (p < 0.001, Figure 2A and 2B). 
With the overexpression of miR-15a-3p and 
miR-16-1-3p in BGC823 cells, the EMT-related 
proteins, which include N-cadherin, α-SMA and 
Fibronectin were all significantly down-regulated 
compared with that of pFlag-CMV2-transfected cells 
(Figure 2A and 2B). Similarly to the results for miRNA 
overexpression, transfection with chemically 
synthesized miR-15a-3p and miR-16-1-3p mimics 
significantly repressed TWIST1 and EMT-related 
protein expression (Figure 2C and 2D). Conversely, 
inhibition of miR-15a-3p and miR-16-1-3p with an 
antisense inhibitor resulted in a dramatic increase in 
the protein level of TWIST1, N-cadherin, α-SMA and 
Fibronectin (Figure 2E and 2F). In addition, 
overexpression of miR-15a-3p and miR-16-1-3p 
decreased the activity of MMP2 and MMP9 (Figure 
S1). Together, these results indicate that 
overexpression of miR-15a-3p and miR-16-1-3p 
effectively suppressed the expression of TWIST1 and 
a group of EMT-related proteins, indicating that 
miR-15a-3p and miR-16-1-3p can serve as key 
regulators involved in EMT process.  
Overexpression of miR-15a-3p and miR-16-1- 
3p suppress GC cell migration and invasion, 
whereas co-transfection of Twist1 ameliorated 
the loss of cell migration and invasion 
To evaluate the impact of miR-15a-3p- and 
miR-16-1-3p-mediated regulation of Twist1, we 
overexpressed miR-15a-3p and miR-16-1-3p in 
BGC823 cells and performed wound healing and 
transwell experiments. In human BGC823 cells, 
overexpression of miR-15a-3p and miR-16-1-3p 
greatly suppressed cell migration (Figure 3A), 
however, co-transfection with a HA-tagged Twist1 
overexpressing plasmid significantly restored the 
inhibition of cell migration (Figure 3A). To further 
determine whether overexpression of miR-15a-3p and 
 
Figure 2. miR-15a-3p and miR-16-1-3p repress TWIST1 and EMT-related protein expression. (A and B) overexpression of miR-15a-3p and miR-16-1-3p 
significantly repressed TWIST1, N-cadherin, α-SMA and Fibronectin protein expression. (C and D) transfection of miR-15a-3p and miR-16-1-3p mimics significantly reduced 
TWIST1, N-cadherin, α-SMA and Fibronectin protein expression. (E and F) inhibition of miR-15a-3p and miR-16-1-3p significantly induced TWIST1, N-cadherin, α-SMA and 
Fibronectin protein expression. BGC823 cells were transfected with miRNA expression plasmids, miRNA mimics or miRNA inhibitor as indicated. Cells were harvested for 
protein analysis 24 h after the transfection. α-tubulin was used for the loading control. Data are represented as the mean ± SEM (n = 3). NS, not significant; *, p < 0.05; **, p < 
0.01; ***, p < 0.001. 
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miR-16-1-3p might affect cell migration and invasion, 
we performed transwell migration and invasion 
assays with BGC823 cells. In the transwell migration 
assays, we found that overexpression of miR-15a-3p 
and miR-16-1-3p significantly decreased the ability of 
cells to migrate through the membrane by 
approximately 37% (p < 0.01) and 44% (p < 0.001, 
Figure 3B and 3D), respectively, whereas Twist1 
co-transfection significantly ameliorated the 
inhibition of cell migration (Figure 3B and 3D). 
Similarly, overexpression of miR-15a-3p and 
miR-16-1-3p significantly decreased the likelihood of 
cell invasion as determined by their ability to 
penetrate the Matrigel-coated membrane (p < 0.001, 
Figure 3C and 3E), and co-transfection of Twist1 
rescued this cell invasion ability (Figure 3C and 3E). 
Together, these data suggest that miR-15a-3p and 
miR-16-1-3p can serve as tumor suppressors of GC 
cell migration and invasion by regulating Twist1.  
 
 
Figure 3. Effects of overexpression of miR-15a-3p and miR-16-1-3p in BGC823 cells on cell migration and invasion. For wound-healing assay, BGC823 cells were 
seeded and transfected with pmiR-15a, pmiR-16-1 or the control plasmid in the presence or absence of pHA-Twist1. 24 hours after the transfection, wound healing was recorded 
in photographs. For the migration and invasion assay, about 5 × 105 BGC823 cells were grown and transfected with pmiR-15a or pmiR-16-1 in the presence or absence of 
pHA-Twist1 for 24 hours. Approximately 2.5 × 104 transfected BGC823 cells were plated in the upper chamber of an 8-μm Transwell insert (BD Biosciences). DMEM medium 
with 5% FBS (serum) was added to the bottom chamber. The rest of the transfected cells were collected for Western blot analysis. After 48 h, migrated and invaded cells were 
stained and counted. Data are expressed as the mean ± SEM (n = 3). NS, not significant; **, p < 0.01; ***, p < 0.001. (A) overexpression of miR-15a-3p and miR-16-1-3p 
significantly suppressed cell migration, while co-transfection with Twist1 significantly ameliorated the loss of cell migration, as determined in a wound-healing assay. (B and D) 
overexpression of miR-15a-3p and miR-16-1-3p significantly suppressed cell migration, while co-transfection with Twist1 significantly ameliorated the loss of cell migration in 
pmiR-15a or pmiR-16-1 transfected cells, as determined in a transwell assay. (C and E) overexpression of miR-15a-3p and miR-16-1-3p significantly suppressed cell invasion, while 
co-transfection with Twist1 significantly ameliorated the loss of cell invasion in pmiR-15a or pmiR-16-1 transfected cells, as determined in a transwell assay. 
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miR-15a-3p and miR-16-1-3p suppress colony 
formation in vitro 
The significant suppression of migration and 
invasion by miR-15a-3p and miR-16-1-3p expression 
prompted us to further explore the possible biological 
significance of miR-15a-3p and miR-16-1-3p in 
tumorigenesis. As an initial step, the capacity for 
colony formation was evaluated in BGC823 cells that 
were transfected with miRNA overexpressing 
plasmids or control plasmid pFlag-CMV2. 
Interestingly, miR-15a- and miR-16-1-transfected cells 
displayed much fewer and smaller colonies compared 
with pFlag-CMV2-transfected cells (p < 0.001, Figure 
4A and 4B). Additionally, a soft agar colony-forming 
assay was performed to measure 
anchorage-independent growth as a marker for the 
transforming potential of each clone. The soft agar 
colony formation assay showed that miR-15a-3p and 
miR-16-1-3p overexpression significantly reduced the 
ability of soft agar colony formation relative to control 
vector-transfected cells (Figure 4C and 4D). 
Interestingly, cotransfection with a Twist1 
overexpressing plasmid significantly rescued the 
suppression of colony formation ability in BGC823 
cells (Figure 4C and 4D). Together, these results 
demonstrated that miR-15a-3p and miR-16-1-3p 
inhibit cellular transformation by targeting Twist1. 
miR-15a-3p and miR-16-1-3p suppress 
tumorigenicity in vivo, whereas Twist1 
overexpression significantly ameliorated the 
loss of tumorigenicity in nude mice 
 To further confirm the above findings, an in vivo 
model was used. Lentivirus infected BGC823 cells 
(LV-miR-ctrl-, LV-miR-15a-, LV-miR-16-1-, 
LV-miR-15a+LV-Twist1- or LV-miR-16-1+LV-Twist1- 
infected BGC823 cells) were injected s.c. into the right 
posterior flank of nude mice. In nude mice, tumor 
growth of LV-miR-15a- and LV-miR-16-1-infected 
cells was much slower than that with LV-Ctrl-infected 
BGC823 cells (p < 0.001, Figure 5A), however, Twist1 
overexpression significantly ameliorated the 
inhibition of tumorigenicity (p < 0.05 and p < 0.001, 
Figure 5A). The tumor became palpable from 7 to 10 
days after inoculation and grew from average of 45 to 
318 mm3 at the end of the observation. When 
dissected at the end of the study (day 25), the average 
tumor weight of the miR-15a-3p and miR-16-1-3p 
overexpressed group were only 33.3% (p < 0.01) and 
36.1% (p < 0.001) of that of the control group (Figure 
5B and 5C). Co-infection of LV-Twist1, however, 
significant improved the tumor growth compared 
with LV-miR-15a- or LV-miR-16-1-infected group (p < 
0.01 and p < 0.05, Figure 5B and 5C). In the 
miR-15a-3p and miR-16-1-3p overexpressing tumor 
 
Figure 4. Overexpression of miR-15a-3p and miR-16-1-3p significantly inhibits GC cell colony formation. (A and B) the effect of miR-15a-3p and miR-16-1-3p on 
the colony formation of BGC823 cells. Representative results of colony formation of pFlag-CMV2-, pmiR-15a- and pmiR-16-1-transfected BGC823 cells. 24 hours after 
transfection, 200 transfected cells were placed in a fresh six-well plate and maintained in DMEM containing 10% FBS for 2 wk. The rest of the transfected cells were collected 
for Western blot analysis. Colonies were fixed with methanol and stained with 0.5% crystal violet in 50% methanol for 30 min. (C and D) overexpression of miR-15a-3p and 
miR-16-1-3p significantly suppressed colony formation, while co-transfection with Twist1 significantly ameliorated the loss of cell colony formation, as determined in a soft agar 
assay. Data are expressed as the mean ± SEM (n = 3). ***, p < 0.001. 
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tissues, TWIST1 protein was greatly decreased (p < 
0.01 and p < 0.001, Figure 5D). These results indicate 
that the introduction of miR-15a-3p and miR-16-1-3p 
significantly inhibits tumorigenicity of BGC823 cells 
in a nude mouse xenograft model. 
Inverse correlation between miR-15a-3p and 
miR-16-1-3p expression and Twist1 mRNA and 
protein expression in GC clinical samples 
To explore the relationship between the 
expression of miR-15a-3p and miR-16-1-3p and the 
expression of Twist1 mRNA and protein, we 
performed qPCR and Western blots with 20 pairs of 
clinical samples. In approximately 70%~80% of the 
human GC tissues, miR-15a-3p (14 out of 20, Figure 
S2A) and miR-16-1-3p (16 out of 20, Figure S2B) were 
significantly down-regulated in comparison with 
controls, while Twist1 mRNA and protein expression 
levels were greatly increased (15 out of 20, Figure S2C 
and Figure 6A). Correlation analyses demonstrated 
significant inverse correlations between the 
expression of miR-15a-3p and miR-16-1-3p and the 
expression of Twist1 mRNA (p < 0.01 and p < 0.001, 
Figure 6B and 6C) or protein (p < 0.001, Figure 6D and 
6E) in the 20 pairs of GC samples tested. However, no 
apparent association was found between miR-15a-3p 
and miR-16-1-3p expression with patient gender, 
patient age, tumor location, TNM staging or lymph 
node status (data not shown). We further analyzed the 
expression of miR15a-3p, miR-16-1-3p and Twist1 
mRNA in two types of GC by Ming's classification 
[32]. Remarkably, expression of miR-15a-3p and 
miR-16-1-3p were lower in the infiltrative (INF) type 
of GC (p < 0.01 and p < 0.05, Figure 6F and 6G), while 
Twist1 mRNA were highly expressed in the INF type 
of GC compared to the expanding (EXP) type of GC (p 
< 0.05, Figure 6H). This result suggested that the 
down-regulation of miR-15a-3p and miR-16-1-3p may 
affect the microenvironment of GC by targeting 
Twist1 to impact the invasion of tumor.  
 
Figure 5. Overexpression of miR-15a-3p and miR-16-1-3p significantly inhibits tumor growth, while Twist1 ovexpression significantly ameliorated the loss 
of tumor growth in nude mice xenografted with GC cells. BGC823 cells were infected with LV-miR-Ctrl, LV-miR-15a and LV-miR-16-1 lentivirus in the presence or 
absence of LV-Twist1. 24 hours after the infection, cells were harvested and suspended in PBS and then inoculated subcutaneously (~1 × 106 cells/100 ml/mouse) into the right 
side of the posterior flank of 6-week-old nude mice. Data are expressed as the mean ± SEM (n = 4). NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001. (A) Time-dependent 
growth of xenograft tumor tissues in nude mice. (B) Tumor growth in nude mice 25 days after injection with LV-miR-ctrl-, LV-miR-15a-, LV-miR-16-1-, LV-miR-15a+LV-Twist1- 
or LV-miR-16-1+LV-Twist1-infected cells. (C) Comparison of tumor weights. (D) Altered expression of TWIST1 in dissected tumor tissues. 
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Figure 6. Analysis of miR-15a-3p, miR-16-1-3p and Twist1 expression in GC samples. (A) Western blot demonstrating the protein expression level of TWIST1 in GC 
tissues. (B and D) inverse correlation between the expression of miR-15a-3p and the expression of Twist1 mRNA/protein in 20 pairs of GC clinical samples. (C and E) inverse 
correlation between the expression of miR-16-1-3p and the expression of Twist1 mRNA/protein in 20 pairs of GC clinical samples. (F) the expression level of miR-15a-3p in EXP 
and INF types of GC tissues. (G) the expression level of miR-16-1-3p in EXP and INF types of GC tissues. (H) the expression level of Twist1 in EXP and INF types of GC tissues. 
Abbreviations: T, GC tissue; N, adjacent noncancerous gastric tissue; 18S rRNA and U6 mRNA were calibrated for qPCR analysis; β-actin was used as a control for protein 
loading. EXP, expansive type of gastric cancer; INF, infiltrative type of gastric cancer. 
 
Discussion 
TWIST1, a member of the basic helix-loop-helix 
transcription factor family is an oncoprotein with 
important roles in the EMT process [33]. Studies 
showed that Twist1 is overexpressed in a variety of 
human tumors and dysregulation of Twist1 has been 
associated with different types of cancers, and that 
Twist1 over-expression or down-regulation is 
correlated with tumor invasion and metastasis [20, 34, 
35]. A great number of studies reported the role of 
Twist1 in GC [36, 37]. Quantitative real-time PCR 
analysis showed that Twist1 mRNA was 
overexpressed in diffuse-type adenocarcinoma [36]. 
Yan-Qi et al. found that TWIST1 protein expression 
was significantly increased in diffuse-type gastric 
carcinoma and was correlated with lymph node 
metastasis in GC patients [37]. However, the 
regulatory mechanisms underlying dysregulation of 
Twist1 were elusive. Here, we show that miR-15a-3p 
and miR-16-1-3p repress the mRNA expression of 
Twist1 by interacting with the MREs on the 3’ UTR. 
Consistent with previous studies, the expression of 
N-cadherin, α-SMA and Fibronectin [18], biomarkers 
of the EMT process, were down-regulated by Twist1 
repression after the overexpression of miR-15a-3p and 
miR-16-1-3p (Figure 2A, 2B, 2C and 2D). Furthermore, 
overexpression of miR-15a-3p and miR-16-1-3p 
significantly suppressed migration and invasion, 
thereby suppressing the ability of BGC823 cells to 
form colonies in vitro, and suppressing their ability to 
develop tumors in vivo in nude mice. Importantly, our 
demonstration that inhibition of Twist1 by 
overexpression of miR-15a-3p and miR-16-1-3p 
ameliorated GC development suggesting that 
miR-15a-3p and miR-16-1-3p might be important 
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therapeutic targets for prevention or treatment of GC 
and other EMT-associated cancers. 
Several studies have found that abnormal 
expression of miRNAs was directly involved in the 
regulation of the genesis and development of GC 
[38-40]. Microarray analysis showed that 22 miRNAs 
were up-regulated and 6 miRNAs were 
down-regulated in GC [38]. Petrocca et al. found that 
the miR-106b-25 miRNA cluster is involved in E2F1 
posttranscriptional regulation and may play a key 
role in the development of TGF-β resistance in GC 
[39]. miR-21 was overexpressed in GC clinical samples 
and could serve as an efficient diagnostic marker for 
GC [40]. In humans, miR-15a-3p and miR-16-1-3p are 
members of the miR-15 miRNA cluster located at 
13q14.3 [41]. Dynamic regulation of the expression of 
members of miR-15 cluster miRNAs is associated with 
B-cell development [41] in chronic lymphocytic 
leukemia (CLL), deletion of the normal allele [42], 
multidrug resistance in human GC cells [43] and 
B-cell abnormality in systemic lupus erythematosus 
(SLE) [44]. Ectopic expression of miR-15a and 
miR-16-1 suppressed gastric cancer cell proliferation 
by targeting YAP1 protein expression to exert tumor 
suppressor function in gastric adenocarcinoma [45]. A 
recent study also showed that miR-15a was 
significantly reduced in gastric cancer and inversely 
correlated with the protein expression of Bmi-1 [46]. 
Other evidence also suggests that the miR-15 cluster 
miRNAs can induce apoptosis by negatively 
regulating Bcl2 [47]. Aberrant immune and 
inflammatory responses represent key 
pathophysiological process that play important roles 
in the development of tumors [48]. Interestingly, we 
found that miR-15a-3p and miR-16-1-3p suppress 
EMT process by regulating Twist1, suggesting that 
the immune and inflammatory response can work 
together with tumor signaling pathways to influence 
tumor development.  
An important finding in this study is that 
miR-15a-3p and miR-16-1-3p significant decreased in 
the expression in tumor samples taken from patients 
with GC compared to control biopsies of healthy 
tissue. Meanwhile, miR-15a-3p and miR-16-1-3p were 
negatively corrected with Twist1 in GC samples. This 
result indicates that abnormal down-regulation of 
miR-15a-3p and miR-16-1-3p contributed to EMT 
regulation in tumor invasion and metastasis. 
Interestingly, additional differences were discerned 
between expansive and infiltrative type of GC, with 
even lower amounts of the two miRNAs being 
present in the infiltrative type of GC. One possible 
explanation for this finding is that miR-15a-3p and 
miR-16-1-3p can affect the microenvironment by 
regulating the EMT process. In a possible scenario 
(Figure 7), the abnormal down-regulation of 
miR-15a-3p and miR-16-1-3p in GC induced the 
up-regulation of Twist1 and Bcl2, which, in turn, 
trigger the EMT process and suppress cell apoptosis 
respectively. Together, EMT promotion and apoptosis 
inhibition are both associated with tumor cell 
invasion and metastasis. These results suggest that 
miR-15a-3p and miR-16-1-3p may play a role in the 
pathogenesis of GC, or at least serve as a marker of the 
condition. The expression levels of miR-15a-3p, 
miR-16-1-3p and Twist1 can provide the basis for the 
clinical diagnosis of GC. Our experiments 
demonstrate that miR-15a-3p and miR-16-1-3p can 
severe as tumor suppressor genes, repressing the 
EMT process by targeting the Twist1 gene to inhibit 
the GC cell migration and invasion in vitro and in vivo. 
Therefore, we propose that the specific expression of 
miR-15a-3p and miR-16-1-3p in tumor tissues rather 
than normal tissues is useful for the gene therapy of 
cancers. 
 
 
Figure 7. Proposed scheme for the roles of miR-15a-3p, miR-16-1-3p, 
Twist1, Bcl2 and other EMT related genes in tumor invasion and 
metastasis. The down-regulated mature miR-15a-3p and miR-16-1-3p negatively 
regulate Twist1 expression. The up-regulated Twist1 would quickly induce the 
expression of N-cadherin, α-SMA and Fibronectin and so on. Together these genes 
promote the EMT process in GC and change the microenvironment to promote 
tumor invasion and metastasis. On the other hand, miR-15a-3p and miR-16-1-3p 
negatively regulate the expression of anti-apoptotic gene Bcl2 [47]. The up-regulated 
Bcl2 would suppress GC cell apoptosis to promote tumor development. In addition in 
a previous study [49], Bcl2 could co-express with Twist1, therefore promote 
metastasis and inducing vasculogenic mimicry. 
 
Taken together, our present findings have 
important implications for the elucidation of the 
pathogenic mechanisms underlying GC and for the 
clinical treatment of GC. Theoretically, the 
identification of this novel regulatory mechanism of 
Twist1 by miR-15a-3p and miR-16-1-3p sheds light on 
the elucidation of pathogenic mechanisms involving 
the aberrant expression of miR-15a-3p, miR-16-1-3p 
and Twist1.  
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